How Did We Get Here and What Happens Next?

Simrah Mohammad


Dr. Nick Turner

Senior Director

Options for patients presenting with early-stage non-small cell lung cancer (NSCLC) are rapidly improving. While the impact of perioperative chemotherapy was once a mere 5% improvement in survival compared with surgery alone, drugs targeting driver mutations and chemoimmunotherapy are raising the bar on survival outcomes for early-stage resectable patients.

This white paper looks at where the clinical trends of the last few years have brought us and where these trends may lead us in the near future.

You will learn about:

  • Evolving treatments for early-stage NSCLC patients
  • The latest thinking on perioperative treatment strategy and optimal approach
  • Emerging unmet medical challenges that require urgent attention

Download your free copy of “Early-Stage Resectable NSCLC: The Shifting Clinical Paradigm” to ensure you are up to date with the latest developments in this promising area of medicine.

Download your free copy by completing the form.